ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma

... Read more

ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma

... Read more

ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results

... Read more

Takeda Licenses Rights to

... Read more

Takeda Licenses Rights to

... Read more

ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant

... Read more

Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and

... Read more

U.S. Food and Drug

... Read more

Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle

... Read more

Immunomedics Delivers Business Updates, Announces Private Placement Offering

... Read more